Filtern
Volltext vorhanden
- ja (20)
Gehört zur Bibliographie
- ja (20)
Erscheinungsjahr
Dokumenttyp
Sprache
- Englisch (20)
Schlagworte
- HIV (4)
- antiretroviral therapy (3)
- German Hepatitis C-Registry (2)
- chronic hepatitis C (2)
- graft versus host disease (2)
- hepatitis C virus (2)
- infection (2)
- sofosbuvir (2)
- therapeutic drug monitoring (2)
- AIDS (1)
- APRI (1)
- ARDS (acute respiratory distress syndrome) (1)
- BRAF mutation (1)
- COVID-19 (1)
- CYP2C9 (1)
- CYP3A4 (1)
- D insufficiency (1)
- D serum-levels (1)
- FIB-4 (1)
- Germany (1)
- HBV (1)
- HCV cure (1)
- HCV genotype 2 (1)
- HCV genotype-2 (1)
- HCV infection (1)
- HIV diagnosis and management (1)
- HIV infections (1)
- HIV-1-infected patients (1)
- HIV-1-infected subjects (1)
- HIV-infected patients (1)
- IL28B polymorphisms (1)
- LINE-1 retrotransposition (1)
- Prednisolon (1)
- Ruxolitinib (1)
- T cells (1)
- Tansania (1)
- Tanzania (1)
- Uganda (1)
- acoustic radiation force impulse imaging (1)
- active antiretroviral therapy (1)
- adults (1)
- afatinib (1)
- all-cause mortality (1)
- antimicrobial resistance (1)
- antiretrovirals (1)
- at-home sampling (1)
- bile (1)
- biomarkers (1)
- chemokines (1)
- chronic Hepatitis C (1)
- cirrhosis (1)
- coagulation (1)
- common genetic determinants (1)
- cytochrome P450 3A4 (CYP3A4) (1)
- cytotoxic T cells (1)
- dabrafenib (1)
- differentiated thyroid tumor (1)
- direct-acting antiviral (1)
- direct-acting antivirals (1)
- disease (1)
- drug adherence (1)
- drug interactions (1)
- drug monitoring (1)
- drug–drug interactions (DDIs) (1)
- elderly persons (1)
- epidemology (1)
- fibrin D-dimer (1)
- fibrotest (1)
- glecaprevir/pibrentasvir (1)
- healthy volunteers (1)
- highly-active antiretroviral therapy (1)
- human hepatic cells (1)
- hydroxy-dabrafenib (1)
- i-131 uptake (1)
- immune activation (1)
- immune cells (1)
- indinavir (1)
- intensive care medicine (1)
- interferon alpha (1)
- interferon-free (1)
- interleukin-6 (1)
- kinase inhibitors (1)
- liquid chromatography tandem mass spectrometry (LC-MS/MS (1)
- liver (1)
- liver diseases (1)
- management (1)
- melanoma (1)
- mutation databases (1)
- non-invasive fibrosis assessment (1)
- osimertinib (1)
- pandemia (1)
- peginterferon alpha-2B (1)
- peginterferon alpha-2b (1)
- pharmacokinetic interaction (1)
- pharmacokinetics (1)
- physiologically based pharmacokinetic (PBPK) modeling (1)
- plasma D-dimer (1)
- point shear wave elastography (1)
- population pharmacokinetics (1)
- posaconazole (1)
- prostate cancer (1)
- randomized controlled-trial (1)
- real world evidence (1)
- reverse-transcriptase inhibitors (1)
- routine clinical-practice (1)
- ruxolitinib (1)
- sequence databases (1)
- severe fibrosis (1)
- steatosis (1)
- sustained virological response (1)
- therapy (1)
- toxicity (1)
- trametinib (1)
- transient elastography (1)
- viral clearance (1)
- viral load (1)
- viral replication (1)
- virus infection (1)
- volumetric absorptive micro-sampling (VAMS) (1)
- weight gain (1)
Institut
- Medizinische Klinik und Poliklinik II (15)
- Institut für Virologie und Immunbiologie (5)
- Medizinische Klinik und Poliklinik I (5)
- Institut für Pharmazie und Lebensmittelchemie (4)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Institut für Klinische Epidemiologie und Biometrie (1)
- Institut für Mathematik (1)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (1)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (1)
- Missionsärztliche Klinik (1)
Sonstige beteiligte Institutionen
EU-Projektnummer / Contract (GA) number
- 241447 (1)
Ruxolitinib (RUX) is approved for the treatment of steroid-refractory acute and chronic graft versus host disease (GvHD). It is predominantly metabolized via cytochrome P450 (CYP) 3A4. As patients with GvHD have an increased risk of invasive fungal infections, RUX is frequently combined with posaconazole (POS), a strong CYP3A4 inhibitor. Knowledge of RUX exposure under concomitant POS treatment is scarce and recommendations on dose modifications are inconsistent. A physiologically based pharmacokinetic (PBPK) model was developed to investigate the drug–drug interaction (DDI) between POS and RUX. The predicted RUX exposure was compared to observed concentrations in patients with GvHD in the clinical routine. PBPK models for RUX and POS were independently set up using PK-Sim\(^®\) Version 11. Plasma concentration-time profiles were described successfully and all predicted area under the curve (AUC) values were within 2-fold of the observed values. The increase in RUX exposure was predicted with a DDI ratio of 1.21 (C\(_{max}\)) and 1.59 (AUC). Standard dosing in patients with GvHD led to higher RUX exposure than expected, suggesting further dose reduction if combined with POS. The developed model can serve as a starting point for further simulations of the implemented DDI and can be extended to further perpetrators of CYP-mediated PK-DDIs or disease-specific physiological changes.